Alcon has announced the launch of CyPass® Micro-Stent which is implanted in the eye of those who have mild to moderate glaucoma. The stent was developed by Transcend Medical, Inc. which was acquired by Alcon this year (2016).
The device has been approved by US Food and Drug Administration for use in primary open-angle glaucoma patients.
Sergio Duplan, Region President, North America, Alcon says “This new treatment option for cataract patients with mild to moderate primary open-angle glaucoma has been demonstrated to have a lasting, significant IOP-lowering effect.”
The CyPass Micro-Stent device is implanted during cataract surgery, just below the surface of the eye, into the supraciliary space. It is designed to lower IOP by enhancing aqueous outflow through one of the natural drainage pathways of the eye, with minimal tissue disruption, which allows the excess fluid in the eye to drain. The CyPass Micro-Stent was developed by Transcend Medical, Inc. which Alcon acquired in February 2016.
Alcon has also presented two- and three-year data from COMPASS, the largest study of minimally invasive glaucoma surgery to date, as well as findings from the CYCLE study conducted in the European Union.[Image by National Eye Institute / CC BY 2.0]